Poster Session B - Monday Morning
Category: Functional Bowel Disease
Kavan M. Mulloy, BS
Miami Miller School of Medicine
Miami, FL
Clinical Feature | HαTS | IBS | IBD |
Age of Onset | Unknown | 20-30 y/o | major peak 15-25 y/o, minor peak 50-70 |
Male:Female | Male = Female | Female > Male | Male = Female |
Western Prevalence | ~5% of Caucasians | 10-20% | 1.3% |
Common Symptoms and Signs | Diarrhea predominant, crampy abdominal, pain, GERD, flushing, and pruritus | Diarrhea and/or constipation, crampy abdominal pain, GERD | Diarrhea, crampy abdominal pain, bloody stools, bowel fistulas, intestinal strictures/fibrosis, weight loss, anemia |
Serum Lab Values | Elevated Basal Serum Tryptase (Suspicion Mild-Moderate 6.2-7.9 ng/mL; Suspicion High >8.0 ng/mL) | No significant findings | Elevated C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and Iron deficiency |
Genetic Characterization | Extra allelic copy of alpha tryptase encoding gene on TPSAB1 gene locus2 | Normal | +/- Positive |
Small Bowel Histology | Increased density of Mast Cells forming 2-15 cell clusters | No significant findings | Granulomas, Inflammation, crypt abscesses |
Current Treatments | H1 and H2 antihistamines, Oral Cromolyn, Carbohydrate Restriction*, Compounded Oral Ketotifen**, Sub Q Omalizumab**, Other Biologics** | See 2019 ACG Clinical Guidelines for IBS | Immunomodulation Therapies |